HSPA5 and glioblastoma: Additionally, we observed that the reductions in NRF2 and HSPA5 levels caused by borax treatment were consistent with the results of viability, proliferation and migration assays conducted on U251 and A172 cells, suggesting that targeting these specific factors may potentiate the anti‐cancer effects of borax in GBM treatment.